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ABSTRACT
A major IgG-speciﬁc immunodominant VP1
linear epitope of enterovirus 71 (EV71) strain 41
(5865 ⁄ SIN ⁄ 00009), deﬁned by the core sequence
LEGTTNPNG, was identiﬁed by Pepscan analy-
sis. Oligonucleotides corresponding to the amino-
acid sequence of synthetic peptide SP32 were
cloned and over-expressed in Escherichia coli as
a recombinant glutathione-S-transferase (GST)–
SP32 fusion protein. In ELISAs, this protein did
not react with human anti-EV71 IgG antibodies,
but there was signiﬁcant immunoreactivity
according to western blot analysis. The amino-
acid sequence of SP32 was highly speciﬁc for
detecting EV71 strains in western blot analysis,
and showed no immunoreactivity with monoclo-
nal antibodies raised against other enteroviruses,
e.g., CA9 and Echo 6.
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Enterovirus 71 (EV71) is a single positive-
stranded RNA virus [1], with infection often
manifesting as hand, foot and mouth disease [2],
characterised by ulcerating vesicles on the palate
and vesicular lesions on the hands, feet and
buttocks. The usual method for detecting EV71
in any clinical specimen involves viral isolation,
followed by serotyping with serotype-speciﬁc
antibodies and indirect immunoﬂuorescence
assays. An IgM-based ELISA for EV71 diagnosis
has been reported to have high sensitivity and
speciﬁcity. However, this approach is too labo-
rious, as it involves the use of puriﬁed whole
EV71 virions for detecting anti-EV71 antibodies
[3–5]. Synthetic peptides corresponding to the
VP1 protein of enteroviruses are broadly reactive
in an IgG-based ELISA using sera from patients
infected with enteroviruses, and this approach
has the potential for serodiagnosis of a wide
range of enterovirus serotypes [6]. To detect an
enterovirus of unknown serotype, an assay with
broad reactivity would be useful, but this would
not help to identify a speciﬁc enterovirus.
In the present study, 95 overlapping synthetic
peptides, designated SP1–SP95, that spanned the
entire VP1 sequence of EV71 strain 41
(5865 ⁄ SIN ⁄ 00009) (GenBank accession no.
AF316321) were synthesised by Mimotopes
(Clayton, Australia). EV71 was propagated in
RD cells using minimum essential medium
(Gibco, Rockville, MD, USA), based on cyto-
pathic effects produced as a result of virus
infection. Serum samples were collected from
children attending a paediatric outpatient clinic
at the National University Hospital of Singapore,
and these were screened for the presence of anti-
EV71-neutralising antibodies using an in-vitro
microneutralisation assay. A serum-neutralising
titre of ‡1:8 was considered to be positive for
EV71 exposure. Sera containing anti-EV71-
neutralising antibodies (n = 40) were pooled
and designated as EV71-positive sera. Sera with-
out anti-EV71-neutralising antibodies (n = 40)
were pooled and designated as EV71-negative
sera. For assigning linear epitope(s) in ELISAs,
the mean OD obtained from EV71-negative sera
plus twice the standard deviation of the respec-
tive mean was used as the cut-off value.
Two IgG-speciﬁc immunoreactive VP1 linear
regions were identiﬁed, designated as sites I
and II. The ﬁrst region, represented by
synthetic peptides SP14 and SP15 (amino-acid
residues 40–57), was not speciﬁc for detecting
human anti-EV71 IgG, as both peptides also
reacted with EV71-negative sera, perhaps
because of the presence of non-speciﬁc IgG
elicited previously against other enteroviruses
that might harbour similar antigenic determi-
nants. The second immunoreactive region was
represented by synthetic peptides SP31, SP32
and SP33 (amino-acid residues 91–111), and
these were highly speciﬁc for detecting human
anti-EV71 IgG. This region, deﬁned by the core
sequence LEGTTNPNG, represents the major
immunodominant VP1 linear epitope of EV71.
When SP32 (DLPLEGTTNPNGYAN) was tested
against EV71-positive sera, there was signiﬁcant
immunoreactivity towards SP32, which con-
tained the core sequence.
The VP1 protein of the prototype EV71 BrCr
strain (GenBank accession no. U00871), when
produced as a recombinant His–VP1 fusion
protein, was highly insoluble and therefore
required denaturation and renaturation before
it could be used as a capture antigen in western
blots [7]. This insolubility could be attributed to
several hydrophobic transmembrane regions
within VP1. When a smaller peptide without
these regions was used, the immunodominant
VP1 linear epitope represented by SP32 was
over-expressed as a soluble recombinant gluta-
thione-S-transferase (GST)–SP32 fusion protein.
Based on the Kyte and Doolittle hydrophobicity
proﬁle [8], this region (SP32) was shown to be
mainly hydrophilic. Using a protein–protein
BLAST search (blastp v.2.2.14; http://www.
ncbi.nlm.nih.gov), the amino-acid sequence of
SP32 was revealed to be highly homologous to
EV71 strains, indicating its probable high sensi-
tivity as a capture antigen for detecting human
anti-EV71 IgG. Hence, a pair of positive- and
negative-sense oligonucleotides was designed,
based on the nucleotide sequence of SP32
(nucleotides 280–324 of the VP1 gene). For
annealing, both oligonucleotides were heated at
90C for 3 min, and then incubated at 37C for
15 min. Primers ﬂanking the VP1 gene (nucle-
otides 2442–3332 of the complete genome of
EV71 strain 41) were also constructed: GST–
VP1F, 5¢-TGGATCCGGAGATAGAGTGGCAG
(the BamH1 restriction site is underlined) and
GST–VP1R, 5¢-GCCGAAGTCGACTCAAAGGG
TAG (the SalI restriction site is underlined).
The vector pGEX-6p-1 (GE Healthcare Life
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Sciences, Little Chalfont, UK) was used to
construct recombinant GST–SP32 and GST–VP1
fusion proteins, following the procedure recom-
mended by the manufacturer.
The efﬁcacy of the recombinant GST–SP32
fusion protein as a capture antigen for human
anti-EV71 IgG was evaluated in IgG-based ELISA
and western blot assays. No signiﬁcant immuno-
reactivity was detected by ELISA, but because of
its native state, the antigenic site represented by
SP32 could have been masked by the larger GST
protein moiety, thereby hindering antigen–anti-
body interactions. However, the fusion protein
was immunoreactive against human anti-EV71
IgG in western blots, probably because of its
denatured state, in which the steric hindrance
caused by the GST protein would have been
removed, thereby exposing the immunogenic
region represented by SP32. Before being used
as a capture antigen, EV71 was heat-inactivated at
56C and the amount of viral protein was quan-
tiﬁed using the Bradford protein assay (Bio-Rad
Laboratories, Hercules, CA, USA). Both the
recombinant GST–VP1 fusion protein and the
whole EV71 virion were non-speciﬁc when used
as capture antigens in western blots for detecting
human anti-EV71 IgG. This was attributed to the
presence of numerous common linear epitopes
among enteroviruses [6,9–11]. It is believed that
the cross-reactivity may be attributed to human
anti-poliovirus IgG, present in most paediatric
patients as a result of the national childhood
immunisation programme.
In conclusion, the recombinant GST–SP32
fusion protein, harbouring the immunodominant
VP1 linear epitope of EV71, demonstrated high
speciﬁcity and sensitivity, and was a better cap-
ture antigen in western blots than the recombinant
GST–VP1 fusion protein and the whole EV71
virion. This suggests that the recombinant
GST–SP32 fusion protein could be further devel-
oped as a serological reagent for the detection of
human anti-EV71 IgG, and could be used as a
tool for identifying EV71 infection and as a
conﬁrmatory assay for recognising previous
EV71 exposure.
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